New pharmacokinetics and biomarker data from the Georgetown Nilotinib trial
 

Georgetown released some new pharmacokinetics and other biomarker data in a new report. Keep in mind it was just signal dose on small sample. I didn’t see anything groundbreaking here.

BPS Publications

?
 

I did a quick read on this. Did I miss anything on patient symptoms improving?

Some more data but what a waste of a study. I can't see how much can be learned from a single dose. No discussion of how this moved any up the road to approval/validation as a useful drug.

This was just pharmacokinetics and biomarker data analysis. We’re all still waiting for primary and secondary objective results which would give indications about efficacy. Some of the reported results in this article were very strange.